Cargando…
Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin
In the current study, the metabolic effects of atorvastatin dose escalation versus atorvastatin/fenofibric acid combination were compared using metabolomics analyses. Men and women with combined hyperlipidaemia were initially prescribed atorvastatin (10 mg, ≥4 weeks). Patients who reached low-densit...
Autores principales: | Han, Ji Soo, Kim, Kyu, Jung, Youngae, Lee, Jae-Hwan, Namgung, June, Lee, Hae-Young, Suh, Jon, Hwang, Geum-Sook, Lee, Sang-Hak |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168550/ https://www.ncbi.nlm.nih.gov/pubmed/30279504 http://dx.doi.org/10.1038/s41598-018-33058-x |
Ejemplares similares
-
The Efficacy of Fenofibrate in Addition to Atorvastatin in Patients of Type II Diabetes Mellitus
por: Qasim, Muhammad, et al.
Publicado: (2022) -
Rosuvastatin and Atorvastatin: Comparative Effects on Glucose Metabolism in Non-Diabetic Patients with Dyslipidaemia
por: Abbas, Ahmed, et al.
Publicado: (2012) -
Pleiotropic Effects of Atorvastatin and Fenofibrate in Metabolic Syndrome and Different Types of Pre-Diabetes
por: Krysiak, Robert, et al.
Publicado: (2010) -
Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia
por: Rizzo, Manfredi, et al.
Publicado: (2011) -
Emerging Strategies for the Management of Atherogenic Dyslipidaemia
por: Agarwala, Anandita, et al.
Publicado: (2020)